ArticleCentral European journal of public health2026
Impact of COVID-19 on breast cancer screening: time series analysis of pre-pandemic, pandemic and post-pandemic periods.
Article in Central European journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate the impact of the COVID-19 pandemic on breast cancer screening activity, cancer detection rates, and stage at diagnosis by comparing pre-pandemic, pandemic, and post-pandemic periods.
methodsThis retrospective cross-sectional study included women who underwent breast cancer screening between March 2018 and February 2024. The study period was divided into three phases: pre-pandemic (March 2018 - February 2020), pandemic (March 2020 - February 2022), and post-pandemic (March 2022 - February 2024). Screening activity, including mammography and breast ultrasonography examinations, cancer detection rates, age at diagnosis, tumour size, and stage distributions were evaluated.
resultsA total of 102,833 women underwent breast cancer screening during the study period. Significant differences were observed in the numbers of screened women, mammography examinations, ultrasound examinations, and breast cancers detected across the study periods (all p < 0.001). The cancer detection rate increased from 10.64 per 1,000 screened women in the pre-pandemic period to 12.68 during the pandemic and 16.32 in the post-pandemic period (p < 0.001). Early-stage diagnoses decreased from 84% to 72%, whereas advanced-stage diagnoses increased from 16% to 28% (p = 0.002). The proportion of metastatic disease increased from 5.6% to 22% (p = 0.028). No significant differences were observed in age at diagnosis (p = 0.896), tumour size (p = 0.201), or T stage distribution (p = 0.519).
conclusionsThe COVID-19 pandemic substantially affected breast cancer screening and diagnosis. Although screening activity declined during the pandemic, cancer detection rates increased and a significant shift toward advanced-stage and metastatic disease was observed in the post-pandemic period. Maintaining resilient and accessible breast cancer screening services during future healthcare crises is essential to minimize diagnostic delays and improve patient outcomes.
Indexed as
Identifiers
42853051What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.